中国综合临床
中國綜閤臨床
중국종합림상
Clinical Medicine of China
2015年
10期
887-890
,共4页
姚秋明%张健%徐健%史良凤%何双涛%张进安
姚鞦明%張健%徐健%史良鳳%何雙濤%張進安
요추명%장건%서건%사량봉%하쌍도%장진안
25-(OH)D3%自身免疫性甲状腺疾病%Graves病%桥本甲状腺炎
25-(OH)D3%自身免疫性甲狀腺疾病%Graves病%橋本甲狀腺炎
25-(OH)D3%자신면역성갑상선질병%Graves병%교본갑상선염
25-hydroxyvitamin D3%Autoimmune thyroid diseases%Graves' diseases%Hashimoto's thyroiditis
目的 探讨血清25-(OH) D3与自身免疫性甲状腺疾病(AITD)之间的关系.方法 选取初诊Graves病(GD) 32例、顽固性GD17例、缓解性GD10例、桥本甲状腺炎(HT)35例,健康查体者58名,检测血清25-(OH) D3和甲状腺自身抗体,包括促甲状腺素受体抗体(TRAb)、抗甲状腺球蛋白抗体(TGAb)、抗甲状腺过氧化物酶抗体(TPOAb)及甲状腺功能,并对25-(OH) D3水平与其他指标进行相关分析.结果 与对照组相比,初诊GD组及HT组血清25-(OH) D3均显著降低[(50.75±17.60)、(36.63±21.65)、(43.05±19.53) μg/L],差异均有统计学意义(P均＜0.05).顽固性GD与缓解性GD组血清25-(OH) D3水平差异无统计学意义[(32.43±17.50)、(31.88±14.48) μg/L,P=0.866],但与对照组相比,差异均有统计学意义(P均＜0.05).GD组25-(OH) D3与TRAb、FT3、FT4、TSH之间无相关性,HT组25-(OH) D3与TGAb、TPOAb、FT3、FT4、TSH之间无相关性(P均＞0.05).结论 AITD患者外周血中25-(OH) D3的含量较对照组显著降低,推测维生素D的免疫抑制作用可成为治疗AITD的潜在手段,未来仍需进一步阐明25-(OH)D在AITD中发挥的具体作用.
目的 探討血清25-(OH) D3與自身免疫性甲狀腺疾病(AITD)之間的關繫.方法 選取初診Graves病(GD) 32例、頑固性GD17例、緩解性GD10例、橋本甲狀腺炎(HT)35例,健康查體者58名,檢測血清25-(OH) D3和甲狀腺自身抗體,包括促甲狀腺素受體抗體(TRAb)、抗甲狀腺毬蛋白抗體(TGAb)、抗甲狀腺過氧化物酶抗體(TPOAb)及甲狀腺功能,併對25-(OH) D3水平與其他指標進行相關分析.結果 與對照組相比,初診GD組及HT組血清25-(OH) D3均顯著降低[(50.75±17.60)、(36.63±21.65)、(43.05±19.53) μg/L],差異均有統計學意義(P均＜0.05).頑固性GD與緩解性GD組血清25-(OH) D3水平差異無統計學意義[(32.43±17.50)、(31.88±14.48) μg/L,P=0.866],但與對照組相比,差異均有統計學意義(P均＜0.05).GD組25-(OH) D3與TRAb、FT3、FT4、TSH之間無相關性,HT組25-(OH) D3與TGAb、TPOAb、FT3、FT4、TSH之間無相關性(P均＞0.05).結論 AITD患者外週血中25-(OH) D3的含量較對照組顯著降低,推測維生素D的免疫抑製作用可成為治療AITD的潛在手段,未來仍需進一步闡明25-(OH)D在AITD中髮揮的具體作用.
목적 탐토혈청25-(OH) D3여자신면역성갑상선질병(AITD)지간적관계.방법 선취초진Graves병(GD) 32례、완고성GD17례、완해성GD10례、교본갑상선염(HT)35례,건강사체자58명,검측혈청25-(OH) D3화갑상선자신항체,포괄촉갑상선소수체항체(TRAb)、항갑상선구단백항체(TGAb)、항갑상선과양화물매항체(TPOAb)급갑상선공능,병대25-(OH) D3수평여기타지표진행상관분석.결과 여대조조상비,초진GD조급HT조혈청25-(OH) D3균현저강저[(50.75±17.60)、(36.63±21.65)、(43.05±19.53) μg/L],차이균유통계학의의(P균＜0.05).완고성GD여완해성GD조혈청25-(OH) D3수평차이무통계학의의[(32.43±17.50)、(31.88±14.48) μg/L,P=0.866],단여대조조상비,차이균유통계학의의(P균＜0.05).GD조25-(OH) D3여TRAb、FT3、FT4、TSH지간무상관성,HT조25-(OH) D3여TGAb、TPOAb、FT3、FT4、TSH지간무상관성(P균＞0.05).결론 AITD환자외주혈중25-(OH) D3적함량교대조조현저강저,추측유생소D적면역억제작용가성위치료AITD적잠재수단,미래잉수진일보천명25-(OH)D재AITD중발휘적구체작용.
Objective To investigate the relationship between serum 25-(OH) D3 and autoimmune thyroid diseases (AITD).Methods Serum levels of 25-(OH) D3, thyroid antibodies (thyroid stimulating hormone receptor antibody (TRAb), TGAb (thyroid globulin antibody), thyroid peroxidase antibody (TPOAb) and thyroid function of 32 cases patients with Graves' diseases (GD), 17 cases patients without remission of GD,10 cases patients with remission of GD,35 cases patients with Hashimoto's thyroiditis (HT),and 58 cases healthy subjects were measured,and the relationships between serum 25-(OH) D3 and the above clinical index were analyzed.Results The serum level of 25-(OH) D3 in patients with GD or HT were obviously lower than that in healthy subjects((50.75±17.60) μg/L, (36.40±21.65) μg/L, (43.05±19.53) μg/L,P＜0.05).No significant difference of the serum level of 25-(OH) D3 was found between patients refractory of GD and those with GD in remission((32.43±17.50) μg/L, (31.88±14.48) μg/L,P=0.866).However,compared with the normal control group,both diseased groups showed significantly decrease (P＜0.05).No correlation was found between serum 25-(OH) D3 and TRAb, FT3, Fr4 as well as TSH in GD group.No correlation was found between serum 25-(OH) D3 and TGAb, TPOAb (P＞ 0.05).Conclusion Serum vitamin D levels are decreased in patients with AITD, which has been speculated as a potential therapeutic method for AITD, though further investigations are needed to establish the precise role of 25-(OH) D3 in AITD.
